三生国健药业（上海）股份有限公司-瞪羚企业名录-瞪羚企业大全-中商情报网

三生国健药业（上海）股份有限公司

电话：021-50791399

邮箱：暂无

官网： http://www.sunshine-guojian.com

地址：中国(上海)自由贸易试验区李冰路399号

行业：研究和试验发展

领域：生物医药

园区：张江国家自主创新示范区

基本信息

主营业务	生物制品、基因工程产品、中西药业、生物试剂的研究、开发（除人体干细胞、基因诊断与治疗技术开发和应用）；生物工程产品的生产、销售自产产品；相关项目研发成果的技术转让、技术服务和技术咨询。【依法须经批准的项目，经相关部门批准后方可开展经营活动】
企业简介	上海中信国健药业股份有限公司上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中国中信股份有限公司（原“中信泰富有限公司”）投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led byChina International Trust and Investment Corporation（CITIC Limited，formerly "CITIC Pacific Limited"). CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China. Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage. 现由于公司发展需要，诚聘具有创新精神和成就事业理想的优秀人才加盟。请符合条件的应聘者将中英文简历等信息发送E-mail至:hr@cpgj-pharm.com （请在邮件题目上注明应聘职位等信息）

主营业务

生物制品、基因工程产品、中西药业、生物试剂的研究、开发（除人体干细胞、基因诊断与治疗技术开发和应用）；生物工程产品的生产、销售自产产品；相关项目研发成果的技术转让、技术服务和技术咨询。【依法须经批准的项目，经相关部门批准后方可开展经营活动】

企业简介

上海中信国健药业股份有限公司上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中国中信股份有限公司（原“中信泰富有限公司”）投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led byChina International Trust and Investment Corporation（CITIC Limited，formerly "CITIC Pacific Limited"). CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China. Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage. 现由于公司发展需要，诚聘具有创新精神和成就事业理想的优秀人才加盟。请符合条件的应聘者将中英文简历等信息发送E-mail至:hr@cpgj-pharm.com （请在邮件题目上注明应聘职位等信息）

工商信息

统一社会信用代码	91310000735408592G	公司类型	股份有限公司（港澳台投资、上市）
法人	LOU JING	注册资本	61621.1413万元人民币
成立时间	2002-01-25	登记状态	存续
经营期限	2002-01-25 至无固定期限	登记机关	上海市市场监督管理局
经营范围	生物制品、基因工程产品、中西药业、生物试剂的研究、开发（除人体干细胞、基因诊断与治疗技术开发和应用）；生物工程产品的生产、销售自产产品；相关项目研发成果的技术转让、技术服务和技术咨询。【依法须经批准的项目，经相关部门批准后方可开展经营活动】